FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 488 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR How CRISPR is Changing Cancer Research and Treatment July 27, 2020 PDX Mouse Models Are Reliable Stand-Ins for Human Tumors, Study Finds February 2, 2021 ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Load more HOT NEWS Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour A College Senior vs. A Global Pandemic
